Immuneering
Business Services · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
245 Main St PMB 2, Cambridge, Massachuse...Phone Number
(617) 500-8080Website
www.immuneering.comRevenue
$14.4 MillionStock Symbol
IMRXIndustry
About Immuneering
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneerings lead product candidate, IMM-1-104, is an oral, once-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS mutations. IMM-6-415 is an oral, twice-daily Deep Cyclic Inhibitor currently in a Phase 1/2a trial in patients with advanced solid tumors harboring RAS or RAF mutations. The companys development pipeline also includes several early-stage programs.Explore more
Immuneering Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Immuneering
Compare insights from companies similar to Immuneering, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Immuneering Tech Stack
A closer look at the technologies used by Immuneering
See more technologies
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Immuneering
Sign Up For FreeTo access detailed company insights
Immuneering is a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients. The Company aims to achieve universal activity through Deep Cyclic Inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneerings lead product candidate, IMM-1-... Read More
